Effect of Hands and Feet Exercises on Taxane Based Chemotherapy Induced Peripheral Neuropathy in Patients With Solid Tumors

NCT07321236 | Not Yet Recruiting DMC

• 1 other identifier: NHussain
• Study Type: interventional
• Target: 58
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to determine whether hand and foot exercises can reduce the severity of Taxane-based chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer patients aged 20-60 years who have Grade 1I neuropathy as defined by the NCI-CTCAE criteria. The main questions it aims to answer are:

• Do hand and foot exercises reduce the severity of sensory and motor neuropathic symptoms in patients receiving Taxane based chemotherapy?
• Is the severity of peripheral neuropathy lower in the exercise group compared to patients receiving standard care alone? Researchers will compare patients receiving standard care (control group) with those receiving standard care plus a structured hand and foot exercise program (experimental group) to see if the exercises lead to greater improvement in neuropathy severity scores. Participants will:
• Receive baseline assessment using the EORTC QLQ-CIPN20 questionnaire.
• In the experimental group, learn and perform a 15-minute hand and foot exercise routine on chemotherapy day and continue it at home using a provided brochure.
• Participate in telephonic follow-ups to support compliance and monitor symptoms.
• Undergo a follow-up assessment at alternate week to measure changes in neuropathy severity.

Conditions

Peripheral Neuropathy

Keywords

Peripheral neuropathy; Taxane; Chemotherapy

Outcome Measures

Primary Outcomes (1)

• Severity of peripheral neuropathy

  The primary outcome of this study is the severity of chemotherapy-induced peripheral neuropathy in cancer patients receiving Taxane-based chemotherapy. Severity will be measured using the EORTC QLQ-CIPN20 questionnaire, which assesses sensory symptoms (tingling, numbness, burning), motor symptoms (difficulty gripping or walking), and autonomic symptoms (such as dizziness). Each item is scored from 1 (not at all) to 4 (very much), with higher scores indicating more severe neuropathy. Assessments will be conducted at baseline (week 1) and week 8 to determine whether the hand and foot exercise program reduces symptom severity compared to standard care alone.

  6 Months

Study Arms (2)

Standard Care (Control)

NO INTERVENTION

Standard care

Hand and Foot Exercise Program + Standard Care (Experimental)

EXPERIMENTAL

Structured Hand and Foot Exercises and standard care

Other: Structured Hand and Foot Exercises

Interventions

Structured Hand and Foot Exercises OTHER

The intervention consists of a structured hand and foot exercise program specifically designed for patients experiencing chemotherapy-induced peripheral neuropathy during Taxane-based treatment. It is distinct from general physiotherapy or mobility exercises because it targets peripheral nerve function, joint mobility, and circulation in the hands and feet, aiming to reduce the severity of neuropathic symptoms.

Hand and Foot Exercise Program + Standard Care (Experimental)

Eligibility Criteria

• Age: 20 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Cancer patients receiving taxane-based chemotherapy on alternate week.
• Age 20-60 years, both male and female.
• Patients having Grade I neuropathy by NCI-CTCEA criteria.

You may not qualify if:

• Patients with peripheral neuropathy not caused by chemotherapy.
• Patient with type-1 and type- 2 diabetes.
• Patients with neuropsychiatric disorders.
• Patients having any skin ulcer.
• Individuals having hand foot fracture and varicose veins.
• Individuals with paraplegia.
• Patients receiving radiotherapy.

Sponsors & Collaborators

• University of Health Sciences Lahore: lead

Related Publications (1)

• Yeo F, Ng CC, Loh KWJ, Molassiotis A, Cheng HL, Au JSK, Leung KT, Li YC, Wong KH, Suen L, Chan CW, Yorke J, Farrell C, Bandla A, Ang E, Lopez V, Sundar R, Chan A. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Support Care Cancer. 2019 Dec;27(12):4753-4762. doi: 10.1007/s00520-019-04771-8. Epub 2019 Apr 10.

  PMID: 30972646 BACKGROUND

Related Links

• Article: "The effect of hand and foot exercises on peripheral neuropathy and quality of life in women with breast cancer: a randomized controlled trial" (2025).
• Article:A Case Study on the Integrated Rehabilitation of Chemotherapy-Induced Peripheral Neuropathy in a Patient with Stage IV Breast Cancer
• Article: Striding beyond numbness: a non-randomized controlled study of an exercise program for breast cancer patients with chemotherapy-induced peripheral neuropathy

MeSH Terms

Conditions

Peripheral Nervous System Diseases

Condition Hierarchy (Ancestors)

Neuromuscular Diseases; Nervous System Diseases

Study Officials

• Kausar Bano, MBBS, FCPS

  Jinnah Hospital,Lahore.

  STUDY CHAIR

Central Study Contacts

N Hussain, Generic BSN

CONTACT

+923085182487; hussainnusrat640@gmail.com

D Khan, Generic BSN

CONTACT

+923408380021; asadamzhr93@gmail.come

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator (MSN student)

Model Details: Participants will be randomly assigned in a 1:1 ratio to one of two parallel arms and will remain in that assigned arm for the duration of the study.

Study Record Dates

• First Submitted: December 21, 2025
• First Posted: January 6, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): August 2, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: May 6, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share